Boditech Med Inc

Boditech Med Inc maintains a strong liquidity position with a current ratio of 5.24 and cash and equivalents of KRW 19.56 billion, which is well above the industry median. The company's price-to-book ratio of 1.03 and price-to-tangible-book ratio of 1.03 suggest a valuation in line with tangible asset value. The debt-to-equity ratio of 0.08 indicates a conservative capital structure with minimal leverage. Profitability metrics show a return on equity (ROE) of 10.23% and return on assets (ROA) of 8.4%, both exceeding the industry median for advanced medical equipment firms. The company's operating margin of 17.56% (calculated from operating income of KRW 28.48 billion on revenue of KRW 162.09 billion) reflects efficient cost management and pricing power in its core markets. Geographically, Boditech Med Inc's revenue is concentrated in South Korea, with no material international revenue disclosed in the latest financials. The company operates in a single business segment focused on diagnostic equipment and reagents, with no diversification into other healthcare services or products. The company's revenue growth is projected to remain stable, with a current fiscal year outlook showing a 5.2% increase in revenue and a 4.8% increase in operating income. This growth is supported by continued demand for infectious disease diagnostics and expansion in domestic healthcare infrastructure. Risk factors include low liquidity risk and low dilution potential, with no immediate filing-based flags detected. The company's free cash flow of KRW -3.35 billion and capital expenditure of KRW -34.02 billion suggest reinvestment in growth initiatives rather than immediate shareholder returns. Recent filings and transcripts indicate no material changes in business strategy or regulatory environment. The company continues to focus on R&D for new diagnostic products and expansion of its domestic market share.